PRA International, a clinical research company, broke ground in late April 2004 on a 101,000-sf facility in Lenexa, Mo. The facility, sited in the Renner Ridge Corporate Center, is expected to reach completion in approximately one year. PRA International designs and coordinates clinical drug trials locally and around the world.
Scripps/University Biotech Consortium is planning to build a Florida Universities and Scripps East Research Consortium Center adjacent to its planned 364,000-sf facility in Palm Beach County. Sited on 150 acres, the first phase of the $10 million, 15,000-gsf project includes design and construction of a campus gateway, a central utility plant, a large reception area, office suites, and meeting rooms.
M+W Zander U.S. Operations is completing the $3.5-million office and cleanroom construction training center in 60,000 sf of Building 44 at the Watervliet Arsenal in Watervliet, N.Y. A joint venture of Albany NanoTech, Arsenal Business and Technology Partnership, and M+W Zander, the center will train members of the Pipe Fitters Union, the International Brotherhood of Electrical Workers, and sheet metal workers to construct and maintain cleanroom facilities and install precision machinery.
Bayer Animal Health broke ground on March 2, 2004 on a $14-million, 232,000-sf warehousing and distribution center in Shawnee, Kan. Located at the company’s 52-acre site, the facility will warehouse and distribute animal and human pharmaceuticals as well as accommodating office space for a customer call center. Project contractor Clayco of St. Louis is slated to complete construction by year-end 2004. Bayer Animal Health is a division of Bayer HealthCare LLC.
Albuquerque-based TCI Medical plans to break ground on a Carlsbad, Calif., manufacturing plant by June 2004 to produce its medical products. TCI, a startup nuclear pharmaceutical company, provides radioactive isotopes for the diagnosis and treatment of heart ailments, cancer, and circulatory problems.
St. Louis-based Sigma Aldrich Corp. will construct an $8-million laboratory-scale production facility in Hyderabad, India. Expected to be operational by the first quarter of 2005, the 50,000-sf complex will eventually house up to 80 chemists doing contract research and process development for the pharmaceutical industry.
Pharmaceutical company NitroMed Inc. is expanding its corporate headquarters and research facilities with a relocation from Bedford to Lexington, Mass. The site, 52,000-sf of renovated space at the Spring Street Technology Park, was previously the headquarters of Raytheon Co. NitroMed is currently developing nitric oxide-enhancing medicines to treat heart disease.
Bayer Healthcare Diagnostics Division is relocating from Medfield to 100,000-sf in Norwood, Mass. A $5-million wet lab will be developed in the facility prior to occupancy in January 2005.
Pharmaceutical giant Merck is constructing a 300,000-sf facility in the Longwood Medical Area of Boston. Slated to open in late 2004, the 18-story facility will employ 450 workers.
Andrx Corp. has awarded O’Neal Inc. of Greenville, S.C., the contract to renovate the first 70,000 sf of a 480,000-sf Morrisville, N.C., manufacturing facility that Andrx acquired from Bristol-Myers Squibb in 2003. The $23-million first phase will create laboratory, warehouse, packaging, and administrative space. Slated for occupancy in early 2005, the plant will employ 400 workers when it reaches full operational status, nearly doubling Andrx’s manufacturing capacity.
The Eisai Research Institute of Boston, a biopharmaceutical research firm, is planning a $50-million expansion and consolidation project in Andover, Mass. Eisai will break ground in late summer of 2004 on a 150,000-sf facility replacing a 66,825-sf office sited adjacent to the company’s existing 40,000-sf drug discovery facility. A new 5,000-sf addition is also included in the project, which involves the consolidation and relocation of Eisai’s Wilmington lab space to the new facility when it opens in 2006.
Chapel Hill-based Synthon Pharmaceuticals will construct a $20 million pharmaceutical manufacturing plant in Mebane, N.C., that will employ between 100 and 120 workers.
United Therapeutics will construct a 40,000-sf ovarian cancer research lab and pharmaceutical manufacturing building adjacent to its headquarters in Silver Spring, Md. The $15-million lab is part of a 190,000-sf biotechnology campus planned by United Therapeutics. The new facility will manufacture OvaRex, an alternative to chemotherapy, in bulk for shipping to third-party manufacturers that will form it into pills.
Synthon Pharmaceuticals is planning to build a new $20 million pharmaceutical manufacturing facility in Mebane, N.C. The 130,000-sf building will house corporate offices, R&D, and drug manufacturing operations. Groundbreaking is expected in early 2004. Synthon Pharmaceuticals is a wholly-owned subsidiary of Netherlands-based Synthon B.V.
GlaxoSmithKline has opened its new 220,000-sf manufacturing facility in Zebulon, N.C. The facility will employ 250 workers engaged in manufacturing inhaled respiratory products, including a device called the Advair Diskus.
